The RACE for Children Act
Supporting sponsors to get more paediatric oncology drugs to market
Paediatric cancer is the leading cause of death by disease in the US. The intent of the RACE for Children Act is to get more paediatric oncology drugs in the pipeline.
Pharmaceutical and biotechnology companies with oncology departments must adhere to the Research to Accelerate Cures and Equity for Children Act (The RACE for Children Act) which requires that studies and investigations involving products that treat adult cancer must also assess the use of those products in children.
The RACE for Children Act
The RACE for Children Act requires that studies and investigations involving products that treat adult cancer must also assess the use of those products in children.
In this whitepaper, our experts examine: Key success factors for companies, challenges presented by the RACE for Children Act, and successes through collaboration.
Read the whitepaperThe RACE for Children Act prompts more paediatric clinical trials for oncology drug development
In this on-demand webinar, ICON expert Missy Hansen, presents on the paediatric regulatory requirements and study approaches for the development of new medicines, with a particular focus on oncology drug development.
Watch the webinarStay current on the latest updates to the RACE for Children Act:
Paediatrics services
ICON is invested in bringing safe, effective, paediatric-tested treatments to children. Explore our paediatric experience and how we can support your study from early engagement all the way to approval.
Read more about ICON’s services in Paediatrics